Sanofi logo

Sanofi

SANOFI NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹7,112 Cr
Volatility
Moderate
P/E Ratio
21.87
EBITDA
₹507 Cr
Return on Equity
36.45%
Debt to Equity
0.02
Book Value
₹358.68
EPS
₹213.31
52W High
₹5,113.5
52W Low
₹3,054

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

4
  • Company has reduced debt.
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 47.8%
  • Company has been maintaining a healthy dividend payout of 71.8%

Weaknesses

2
  • Stock is trading at 8.57 times its book value
  • The company has delivered a poor sales growth of -8.74% over past five years.

Growth Rate

Revenue Growth
-1.34% higher than 3Y
Net Income Growth
-13.96% lower than 3Y
Cash Flow Change
100%
ROE
1.5%
ROCE
-2.71%
EBITDA Margin (Avg.)
-6.33%

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 44d ago
AI opinion · based on fundamentals
Risk high

Sanofi India Ltd is a debt-free MNC pharmaceutical company with a market cap of Rs 7,619 crore, trading at a PE of 25x and 10.35x book value. The company has delivered strong ROE of 43-48% in recent years but faces persistent revenue decline with compounded sales shrinking at -13% TTM and -9% over five years, while maintaining a dividend yield of 2.23%.

Bull Case 7
  • Company is virtually debt-free, providing financial resilience and flexibility in a challenging operating environment
  • Exceptional return on equity at 43% last year and 48% on a 3-year basis, indicating highly efficient capital utilization despite revenue headwinds
  • Healthy dividend payout ratio of 71.8% with a current dividend yield of 2.23%, offering tangible cash returns to shareholders
  • 5-year ROE of 37% and 10-year ROE of 26% demonstrate sustained long-term profitability well above cost of equity
  • MNC parentage (Sanofi SA) provides access to global R&D pipeline, quality standards, and established brand portfolio in Indian healthcare
  • PE ratio of 25x is relatively moderate for a debt-free MNC pharma company with 40%+ ROE, suggesting valuation is not extreme on an earnings basis
  • 10-year compounded profit growth of 3% shows the company has managed to maintain profitability over the long term despite top-line challenges
Bear Case 8
  • Compounded sales have declined at -13% over the trailing twelve months, indicating accelerating revenue erosion
  • 5-year compounded sales growth of -8.74% reflects a structural and persistent inability to grow the top line
  • Stock price has declined 42% over the past 1 year, reflecting significant market de-rating and negative sentiment
  • Trading at 10.35x price-to-book is expensive for a company with shrinking revenues, suggesting limited margin of safety
  • 3-year stock CAGR of -8% and 5-year CAGR of -8% show prolonged wealth destruction for shareholders
  • TTM compounded profit decline of -13% indicates that margin management is no longer fully offsetting revenue shrinkage
  • 10-year stock CAGR of only 2% shows the company has barely kept pace with inflation over a decade, underperforming broader indices significantly
  • 3-year compounded sales decline of -13% suggests the revenue deterioration is not a one-off event but a sustained multi-year trend

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 42d ago
Headwinds 2
  • CFO resigns effective Sep 2026 Jul 23

    Rachid Ayari resigned as Whole Time Director, CFO, and Key Managerial Personnel effective September 30, 2026. Replacement identification is still in process, creating near-term leadership uncertainty.

  • Senior management personnel exits Jul 31

    Nakul Verma will cease to be Senior Management Personnel on July 31, 2026, transitioning to another Sanofi group role. Combined with the CFO departure, two key executives are leaving within months.

Neutral 2
  • Q2FY27 earnings call Aug 5 Jul 23

    Sanofi India will hold an investor call on August 5, 2026, to discuss unaudited financial results for the quarter and half year ended June 30, 2026.

  • Nakul Verma internal transition Jul 31

    Verma's exit is an internal group transfer rather than a departure from the broader Sanofi organization, disclosed under SEBI Regulation 30.

TL;DR: Sanofi India faces near-term leadership churn with both its CFO and a senior management head exiting by Q3 2026, though both are internal Sanofi group transitions rather than adversarial departures. No operational or financial negatives have surfaced, and Q2FY27 results due August 5 will provide the next fundamental data point. The risk is execution continuity during the leadership transition period; the trend is neutral pending earnings clarity.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
515
491
469
511
464
524
515
536
406
475
420
472
438
Expenses
393
377
370
374
348
404
397
364
311
341
330
330
322
Operating Profit
122
114
100
137
116
120
118
172
95
134
90
143
115
OPM %
24%
23%
21%
27%
25%
23%
23%
32%
23%
28%
22%
30%
26%
Other Income
57
82
77
41
21
2
14
3
9
-22
3
4
6
Interest
1
0
0
0
0
0
0
0
0
0
1
0
0
Depreciation
9
9
9
9
9
9
10
10
9
9
10
9
9
PBT
169
186
167
169
127
113
122
165
94
102
83
138
112
Tax %
27%
18%
18%
19%
19%
27%
25%
28%
26%
26%
26%
26%
26%
Net Profit
123
152
138
137
103
82
91
120
70
76
62
103
84
EPS in Rs
53.43
66.17
59.87
59.39
44.96
35.74
39.7
51.96
30.22
33.04
26.83
44.61
36.3
Figures in ₹ Crores

Profit & Loss

Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025TTM
Sales
1,977
2,193
2,367
2,460
2,771
3,071
2,902
2,957
2,770
2,851
2,013
1,837
1,805
Expenses
1,639
1,817
1,832
1,921
2,146
2,403
2,186
2,194
2,066
2,047
1,522
1,346
1,323
Operating Profit
339
376
535
538
625
667
716
762
704
804
491
491
483
OPM %
17%
17%
23%
22%
23%
22%
25%
26%
25%
28%
24%
27%
27%
Other Income
131
218
66
79
88
33
45
564
204
83
79
-8
-9
Interest
0
0
2
1
1
0
2
2
2
2
2
2
2
Depreciation
97
113
119
102
103
100
82
67
42
40
37
37
36
PBT
373
481
480
515
610
600
677
1,258
864
846
531
445
436
Tax %
29%
33%
37%
37%
38%
31%
29%
25%
28%
29%
22%
27%
—
Net Profit
264
322
304
326
381
414
478
944
621
603
414
327
324
EPS in Rs
115
140
132
142
165
180
208
411
270
262
180
142
141
Div. Payout %
39%
46%
51%
50%
51%
194%
176%
119%
211%
64%
65%
87%
—
Figures in ₹ Crores

Balance Sheet

Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025Jun 2026
Equity Capital
23
23
23
23
23
23
23
23
23
23
23
23
23
Reserves
1,463
1,604
1,860
2,003
2,196
2,419
2,096
2,203
1,253
992
838
726
803
Borrowings
0
0
0
0
0
0
23
25
24
19
19
18
15
Other Liabilities
742
778
658
751
765
802
777
811
772
681
732
488
567
Total Liabilities
2,228
2,405
2,541
2,778
2,984
3,244
2,918
3,061
2,072
1,715
1,612
1,255
1,407
Fixed Assets
648
877
817
769
733
499
464
334
306
315
312
304
291
CWIP
210
22
34
30
21
17
10
13
24
16
18
12
19
Investments
0
0
0
0
0
0
0
0
0
2
0
0
0
Other Assets
1,369
1,505
1,690
1,978
2,230
2,728
2,444
2,714
1,743
1,382
1,281
939
1,098
Total Assets
2,228
2,405
2,541
2,778
2,984
3,244
2,918
3,061
2,072
1,715
1,612
1,255
1,407
Figures in ₹ Crores

Cash Flow

Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating
265
213
322
435
374
412
611
559
399
231
462
438
Investing
61
36
-155
-79
-73
66
276
631
651
36
-178
-11
Financing
-122
-147
-180
-188
-197
-183
-810
-849
-1,583
-878
-392
-448
Net Cash Flow
205
102
-13
168
104
295
78
341
-533
-612
-109
-21
Free Cash Flow
247
184
253
379
317
337
810
574
412
221
426
413
CFO/OP
114
93
101
118
99
96
112
111
94
59
114
111
Figures in ₹ Crores

Ratios

Particulars Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Debtor Days
21
24
22
29
21
27
19
18
17
17
42
35
Inventory Days
179
173
169
151
154
127
107
110
125
202
186
127
Days Payable
122
81
79
119
110
100
93
105
109
89
151
79
Cash Conversion Cycle
78
115
112
61
65
54
33
22
33
130
77
83
Working Capital Days
26
9
79
17
18
35
-8
-20
-19
24
17
7
ROCE %
22%
26%
27%
26%
29%
28%
32%
35%
41%
71%
49%
58%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sanofi insights

67 extracted metrics + investor summaries across FY11–FY26.

Log in — free

Shareholding Pattern

Others2.67%Promot.60.40%FIIs5.69%Public11.38%DIIs19.86%As ofJun 2026

Documents

Frequently Asked Questions about Sanofi

What does Sanofi India Ltd do?
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]
Where is Sanofi India Ltd (SANOFI) listed?
Sanofi India Ltd trades as SANOFI on the NSE and under code 500674 on the BSE.
Which sector does Sanofi India Ltd belong to?
Sanofi India Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Sanofi India Ltd?
Sanofi India Ltd has a market capitalisation of ₹7,112 Cr, which places it in the Mid Cap band.
What is the PE ratio of Sanofi India Ltd?
Sanofi India Ltd trades at a PE ratio of 21.87, on earnings per share of ₹213.31, against a book value of ₹358.68 per share.
What is the 52-week high and low of Sanofi India Ltd?
Over the last 52 weeks Sanofi India Ltd has traded between ₹3,054 and ₹5,113.5.
Does Sanofi India Ltd pay dividends?
Sanofi India Ltd has a dividend yield of 2.41%.
What is the Return on Equity (ROE) of Sanofi India Ltd?
Sanofi India Ltd reported a return on equity of 36.45%. Its debt-to-equity ratio is 0.02.

Company Information

Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.[1]

Website sanofiindialtd.com
CEO Mr. Rachid Ayari
Employees 1,225
Listed 2003-05-19
Face Value ₹ 10
Issued Size 2,30,30,622

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SANOFI.md for Sanofi India Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List